Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.
Read Full NewsCould timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?
Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.
Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.
In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.
1.
An effective treatment for a rare but deadly form of cancer
2.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
3.
The discovery of drug combinations may increase the life expectancy of children with brain cancer.
4.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
5.
How access to specialized cancer centers affects glioblastoma outcomes
1.
Transformative Directions in Hematology in Clinical Decision-Making
2.
Precision to Personalization: Expanding Genetic Testing and Counseling in Oncology
3.
Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals
4.
National Blood Health Promotion Strategies: Evidence-Based Approaches for Improved Outcomes
5.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge